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Introduction
 
Type 2 diabetes mellitus is a common, chronic disease associ-
ated with reduced life expectancy [1–4]. Studies of mortality in
Type 2 diabetes in the UK have commonly used local registers
[1,5]. Such registers have relatively small sample sizes and
potentially insufficient outcome data to provide accurate esti-
mates of risk. Studies using national mortality statistics suffer
because diabetes as a contributory cause is under-reported on
death certificates [4]. A prospective study using a national
general practice database with good prescribing and associated
morbidity and mortality data may provide more reliable
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Abstract
 
Aims
 
Under-reporting of diabetes on death certificates contributes to the un-
reliable estimates of mortality as a result of diabetes. The influence of obesity on
mortality in Type 2 diabetes is not well documented. We aimed to study mortality
from diabetes and the influence of obesity on mortality in Type 2 diabetes in a
large cohort selected from the General Practice Research Database (GPRD).
 
Methods
 
A cohort of 44 230 patients aged 35–89 years in 1992 with Type 2
diabetes was identified. A comparison group matched by year of birth and sex
with no record of diabetes at any time was identified (219 797). Hazards ratios
(HRs) for all-cause mortality during the period January 1992 to October 1999
were calculated using the Cox Proportional Hazards Model. The effects of body
mass index (BMI), smoking and duration of diabetes on all-cause mortality
amongst people with diabetes was assessed (
 
n
 
 = 28 725).
 
Results
 
The HR for all-cause mortality in Type 2 diabetes compared with no
diabetes was 1.93 (95% CI 1.89–1.97), in men 1.77 (1.72–1.83) and in women
2.13 (2.06–2.20). The HR decreased with increasing age. In the multivariate
analysis in diabetes only, the HR for all-cause mortality amongst smokers was
1.50 (1.41–1.61). Using BMI 20–24 kg/m
 
2
 
 as the reference range, for those with
a BMI 35–54 kg/m
 
2
 
 the HR was 1.43 (1.28–1.59) and for those with a BMI 15–
19 kg/m
 
2
 
 the HR was 1.38 (1.18–1.61).
 
Conclusions
 
Patients with Type 2 diabetes have almost double the mortality
rate compared with those without. The relative risk decreases with age. In people
with Type 2 diabetes, obesity and smoking both contribute to the risk of all-cause
mortality, supporting doctrines to stop smoking and lose weight.
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estimates of relative and absolute risk of the mortality associated
with diabetes.
Evidence of the influence of obesity on mortality is conflict-
ing. Studies of obesity in the general population have demon-
strated varying associations with all-cause mortality. Shaper
 
et al
 
. showed a U-shaped association, whilst Calle 
 
et al
 
. described
a J-shaped curve [6,7]. In people with diabetes, Hodge 
 
et al
 
.
described an inverse relationship between mortality and BMI,
Walters 
 
et al
 
. showed no association between obesity and mor-
tality in insulin-treated or non-insulin-treated diabetes, whilst
Rogers 
 
et al
 
. showed a marked increased risk in mortality with
increasing body mass index (BMI) in diabetes [8–10]. This
study aimed to estimate the relative risk of mortality in Type 2
diabetes by age and sex, and the influence of BMI, smoking
and duration of diabetes on mortality in a large cohort of
patients with diabetes drawn from the UK general population.
 
Patients and methods
 
Study population and data source
 
A cohort study was carried out using data from the General
Practice Research Database (GPRD) in patients with Type 2
diabetes and a comparison group without diabetes. The GPRD
provides longitudinal anonymized patient data from general
practices across the UK and includes data on demographics,
medical diagnoses and symptoms, prescriptions and hospital
admissions. Data on patients’ lifestyles such as smoking habit
are also available. The age and sex distribution of the population
on the database at any point in time closely matches that estimated
by the Office for National Statistics for England and Wales in
1998 [11]. Data have been shown previously to be of high quality
and validity, and have been used extensively for cohort and
case-control studies [12–17]. According to the Royal College of
General Practitioners, 98% of people in the UK are registered
with a general practitioner (www.rcgp.org.uk/information/
publications/information/infosheettitles_index.asp ‘General
Practitioner Workload’ April 2004. Data accessed August 2005).
Therefore, using primary care data allows us to study a popula-
tion-based sample of patients with diabetes compared with a
comparison group of people without diabetes drawn from the
same population, but who are otherwise unselected. The version
of the GPRD used for this study includes data from practices
contributing between 1987 and October 1999, representing a
total of 8 066 630 patient records. Only practices that were
supplying data to the GPRD on 1 January 1992 and for at least
6 months prior to 1992 were included in the study.
Ethical permission was given for this study by the GPRD
Scientific and Ethical Advisory Group.
Medical diagnoses and symptoms are recorded on the data-
base using OXMIS (Oxford Medical Information System) or
Read codes (the coding system adopted by the Department of
Health for use in General Practice). All subjects present on the
database on 1 January 1992 with a code or treatment for dia-
betes prior to this date were identified. Patients with a first code
or treatment for diabetes on or after this date were excluded
from the patient and comparison group. To allow comparison
of prevalence with other studies, persons with any diabetes type
were identified initially. Patients with diabetes were those with
a diagnostic code and supporting evidence of diabetes, or treat-
ment for diabetes and other supporting evidence such as home
glucose monitoring or glycated haemoglobin testing. Patients
with Type 1 or Type 2 diabetes were then distinguished using
algorithms based on age at diagnosis, type of treatment and age
at treatment. Patients with Type 2 diabetes were those who had
a diagnosis of diabetes and were treated with diet only or with
an oral hypoglycaemic agent, or if treated with insulin were
aged 35 years or older at diagnosis. Those treated with insulin
only and aged less than 35 years at diagnosis were deemed to
have Type 1 diabetes. Those not selected by the Type 1 or Type 2
algorithms were considered indeterminate. The final cohort for
this study included patients with Type 2 diabetes aged 35–90
years on 1 January 1992. For comparison, five subjects per
patient were selected randomly from the GPRD matched by
year of birth and sex. Comparison subjects had no record of or
treatment for diabetes at any time on the database.
 
Mortality and risk factor detection
 
Deaths after 1 January 1992 were identified from the medical
records using appropriate codes and registration status. Patients
who die whilst registered with a contributing practice are gener-
ally assigned the appropriate deregistration status. All those
with such a registration status were selected as definite deaths.
Where the record contained a code for death but the patient had
not been deregistered, subjects were only included as deaths if
their medical record ended on the same day as the death code
record. Very occasionally there is a death code and no deregis-
tration and the medical record continues. These patients were
not classified as dead.
In the diabetes group, BMI was calculated where height and
weight recordings were available. The readings closest to baseline
were used. Where there was no recording of height or weight
within 3 years of baseline, data were considered missing. Patients
were grouped by BMI range 15–19, 20–24, 25–29, 30–34, and
35–54 kgm
 
2
 
. In the analysis, the range 20–24 kg/m
 
2
 
 was used
as the reference group.
Subjects were categorized as non-smokers, current smokers,
ex-smokers or unknown based on the records of smoking closest
to 1 January 1992, with the exception of some who were classified
as ex-smokers if the closest record to 1992 was for non-smoking,
but they had a prior record of smoking.
Duration of diabetes at baseline was estimated either from
the date of the first OXMIS/Read code for diabetes or the date
of the first diabetes-related prescription, whichever was earlier.
If a general practitioner (GP) is unsure of the date of diagnosis,
however, then this may be recorded as a historical date that
upon investigation proves improbable, if not impossible. These
patients were categorized as unknown duration of diabetes.
 
Statistical analysis
 
A Cox Proportional Hazards Model was used, adjusted for
current age by setting date of birth as the origin and baseline
1 January 1992 as the cohort start date. Hazard ratios (HRs)
were calculated for all-cause mortality in diabetes compared
with no diabetes, and then in diabetes only adjusted for BMI,
smoking and duration of diabetes (patients with missing data
 © 2006 The University of Surrey
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were excluded from this analysis). The analysis was performed
using STATA version 8 (STATA Corp., College Station, TX, USA).
 
Results
 
The GPRD population included 3 616 048 patients on 1 January
1992. We identified 61 097 patients who had codes and/or
prescriptions for the treatment or management of diabetes.
From this cohort we identified 54 703 with a diagnostic code
and supporting evidence of diabetes, or treatment for diabetes
and other supporting evidence such as home glucose monitoring
or glycated haemoglobin testing. The prevalence of all diabetes
on the database in 1992 was 1.5%. The age- and sex-specific
prevalence rates for all diabetes are shown in Fig. 1.
We then categorized 7727 patients with Type 1 diabetes,
and 44 887 with Type 2 diabetes. Those not selected by either
algorithm (8483) as a result of uncertainty of age at diagnosis
or age at first treatment with insulin, or not having a diabetes
code and treatment or evidence of monitoring/follow-up for
diabetes, were deemed indeterminate. Of the 44 887 patients
with Type 2 diabetes, 290 (0.6%) were aged less than 35 years
or 
 
≥
 
 90 years at baseline and thus excluded from study. In a
small proportion of cases (0.8%), death was found to have
occurred late in 1991, but deregistration did not occur until
early 1992. These were considered deaths prior to baseline and
excluded from the cohort. The study is based on 44 230 patients
alive with Type 2 diabetes and aged 35–89 years at baseline
and 219 797 patients without diabetes for the comparison
group. The average age of the study population was 67 years
and 53.2% were male.
There were 11 165 (25.2%) definite deaths in the group
with Type 2 diabetes and 31 742 (14.4%) in the comparison
group. The mortality rate was 60.3 per 1000 person years
(95% CI 59.19–61.42) in the cohort with diabetes and 32.7
(32.34–33.06), in the comparison group. The HR for death in
patients with Type 2 diabetes was 1.93 (1.89–1.97) compared
with people without diabetes. The HR for men [1.77 (1.72–
1.83)] was significantly lower than for women [2.13 (2.06–
2.20)], although men with diabetes were at greater risk than
women with diabetes [HR 1.5 (1.48–1.53)]. The HR was greatest
amongst men and women aged 35–54 years and decreased
with increasing age (Table 1).
In people with diabetes, BMI data were available for 30 839
(70%), whilst smoking data were available for 36 637 (83%).
The duration of diabetes could be ascertained for 42 847 (97%).
Of the diabetes cohort, 65% (28 725) had BMI, smoking and
diabetes duration data (Table 2). The average age was 66 years
and 55% of the group was male. For those not included in the
multivariate analysis, the average age in 1992 was 69.4 years,
and 50% were male and the risk estimates for all-cause mor-
tality was higher than the risk estimate in those with complete
data, HR 2.61 (2.53–2.69) compared with 1.56 (1.51–1.60).
The results of the multivariate analysis of mortality in people
with Type 2 diabetes adjusted for age, sex, duration of diabetes,
smoking and BMI are presented in Table 3. The adjusted
mortality risk was significantly greater in men than in women,
Figure 1 Age- and sex-stratified prevalence of 
all diabetes from the GPRD on 1 January 1992; 
( ) male and () female.
Table 1 Hazard ratios for all-cause mortality in people with Type 2 diabetes compared with people without diabetes by age and sex
 
 
Age 
(years)
Men hazard 
ratio (CI95)
Men (n) with diabetes/
without diabetes
Women hazard 
ratio (CI95)
Women (n) with diabetes/
without diabetes
35–54 3.35 (2.86,3.93)  4042/20 200 3.07 (2.37,3.97)  2523/12 606
55–64 2.21 (2.04,2.39)  6320/31 528 3.28 (2.94,3.65)  4530/22 626
65–74 1.84 (1.75,1.93)  7600/37 774 2.44 (2.30,2.60)  6392/31 840
75–84 1.58 (1.51,1.66)  4853/23 892 1.97 (1.88,2.07)  5824/28 830
85–89 1.44 (1.30,1.60)  732/3553 1.65 (1.52,1.78)  1414/6948
All 1.77 (1.72,1.83) 23 547/11 6947 2.13 (2.06,2.20) 20 683/102 850
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increased with increasing duration of diabetes, and was 50%
greater in smokers and 25% greater in ex-smokers compared
with non-smokers. The mortality risk by BMI has produced a
U-shaped curve. This curve was found in all ages and in both
sexes, although was less pronounced in the older age groups.
Compared with a BMI 20–25 kg/m
 
2
 
, those with a BMI 15–19
or 
 
≥
 
 30 kg/m
 
2
 
 had a statistically increased risk of mortality.
The hazard ratio for BMI 35–54 kg/m
 
2
 
 was significantly greater
than that for BMI 30–34 kg/m
 
2
 
. The exclusion of patients from
the multivariate analysis who had a code for cancer in their
record (
 
n
 
 = 1503) made no difference to the risk estimates for
BMI group, the effect of duration of diabetes and of smoking.
 
Discussion
 
Patients with Type 2 diabetes are at almost twice the risk of
dying from any cause than their peers without diabetes after
adjusting for age. These results are comparable with previous
studies of all-cause mortality in Type 2 diabetes [1,5,18–20].
We did not find the very high relative risks in younger patients
with Type 2 diabetes found in some older studies, which quote
rates of more than five times the mortality of comparison popu-
lations [21,22]. We have produced data from 5585 patients
over the age of 75 years who would often be excluded from a
prospective study or whose number would be few in a small
cohort study. These data suggest that, although their relative
risk of death compared with those with no diabetes is less than
that found in younger patients, they still have a significant
excess mortality and preventive care in these patients is well
worthwhile. Although it should be noted that the absolute
burden of diabetes mortality is greater in men, women with dia-
betes are at a greater proportional risk than women without
diabetes (Table 1). Our prevalence estimate of all diabetes is
consistent with the prevalence reported by other UK studies
conducted between 1992 and 1998 [1,23].
The data on BMI show that amongst patients with diabetes
those with a BMI of 35–54 kg/m
 
2
 
 have a 43% greater risk of
death than those with a ‘normal’ BMI (20–24 kg/m
 
2
 
). The
increased risk amongst those with a BMI 30–34 kg/m
 
2
 
 is also
significantly raised whilst those who are overweight but not
obese have no increase in mortality. This would suggest that
efforts to encourage weight loss should be aimed at the obese
and at preventing those who are overweight from becoming
obese. This study has demonstrated a U-shaped curve associ-
ated with BMI and mortality in diabetes, consistent with that
found by Shaper 
 
et al
 
. in the general population [6]. The high
risk in those with a BMI < 20 kg/m
 
2
 
 is based on mortality in
only 2% of the patients with Type 2 diabetes. The risk in this
group was almost as high as those with a BMI of 35–54 kg/m
 
2
 
.
A small number of patients with a BMI of < 20 kg/m
 
2
 
 would
be expected in a study of people with Type 2 diabetes. This
group was older, more likely to smoke, to be female and to be
treated with insulin (Table 2). The U-shaped curve remained
even when all patients with a diagnostic code for cancer were
excluded, suggesting that this finding was not due to cachexia.
The increased mortality amongst patients with a low BMI may
be associated with weight loss as a result of poorly controlled
diabetes.
There are known limitations of the GPRD. It is not a ‘fixed’
population, i.e. patients may deregister from a contributing
practice or a practice may cease to contribute to the database.
Information on ethnicity is not recorded and there is a slight
over-representation of large practices. It could be said that
general practitioners contributing to the GPRD may have better
management systems leading to better monitoring, recall and
preventive medicine and lower risk estimates and rates. In fact,
the mortality rate in our study is slightly higher than that found
Table 2 Characteristics of patients with Type 2 diabetes where body mass index (BMI), smoking and duration of diabetes are known (n = 28 725)
 
 
BMI 
group 
(kg/m2)
Number of 
patients 
(%)
Percentage 
male
Mean 
age
Number of 
current smokers 
(%)
Number 
prescribed 
insulin (%)
15–19  557 (1.9) 35.6 71 136 (24.4) 124 (22.2)
20–24  6922 (24.1) 58.0 68 1447 (20.9) 1228 (17.7)
25–29 12 489 (43.5) 62.2 66 2422 (19.4) 1548 (12.4)
30–34  5992 (20.9) 50.5 63 1119 (18.7) 667 (11.1)
35+  2765 (9.6) 32.2 60 519 (18.8) 285 (10.3)
Table 3 Multivariate analysis of mortality in people with Type 2 
diabetes adjusted for age, sex, body mass index (BMI), smoking, and 
duration of diabetes (n = 28 725)
 
 
Variable Hazard ratio 95% CI
Male sex 1.33 1.27–1.41
Diabetes duration < 5 years Reference
Diabetes duration 5–9 years 1.14 1.06–1.21
Diabetes duration 10–14 years 1.27 1.17–1.37
Diabetes duration ≥ 15 years 1.38 1.27–1.50
Current smoker 1.50 1.41–1.61
Ex-smoker 1.25 1.15–1.36
Non-smoker Reference
BMI 15–19 kg/m2 1.38 1.18–1.61
BMI 20–24 kg/m2 Reference
BMI 25–29 kg/m2 0.97 0.91–1.03
BMI 30–34 kg/m2 1.13 1.04–1.22
BMI 35–54 kg/m2 1.43 1.28–1.59
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by the Diabetes Audit and Research in Tayside Scotland study,
which reported an annual rate of 50 per 1000 patients with
Type 2 diabetes compared with 60 per 1000 patient years in
our study [24]. Using a large general practice computerized
database has the advantage that a comparison group can be
selected from the same population base as the patients of
interest. We chose a comparison group taken from the GPRD
who were selected on the same criteria as the patients with dia-
betes, except that they had no record of diabetes anywhere in
their record. We randomly selected the comparison group from
all those available on the database but matched by age and sex
so that the age structure of the patients and comparison group
were the same. We did not match by practice because previous
unpublished work by our group has shown practice matching
of large cohort studies does not alter the hazard ratios. Match-
ing by practice reduces the number of available patients in the
older age groups and is in itself a potential source of bias.
A further strength of the study is the opportunity to examine
in people with diabetes the risk estimates associated with BMI,
smoking and duration of diabetes. We were able to ascertain
duration of diabetes, smoking and BMI data in a very large
cohort of 28 725 people with diabetes. Although the hazard
ratio was higher in the patients not included in the multivariate
than for those who had complete data, we believe the findings
from such a large cohort of patients with Type 2 diabetes being
managed in primary care are of value. It is likely that the indi-
viduals who have complete data attend more regularly and thus
benefit from treatment to reduce the risk of complications.
When assessing the risk in the comparison group it is import-
ant to highlight that those with diabetes diagnosed after January
1992 were excluded from the potential comparison group prior
to selection. According to Harris 
 
et al
 
., the average time from
onset to diagnosis of Type 2 diabetes is 4–7 years [25]. There-
fore, as our follow-up period was of this length, most of those
with undiagnosed diabetes will have been excluded from the
comparison group. However, the comparison group will still
contain a small number of patients with undiagnosed diabetes.
It is likely that these patients may have made a small contribu-
tion to the risk estimates of the comparison group, which would
marginally reduce the risk estimates reported here. However,
the absence of known diabetes in the comparison group makes
the risk estimates in our study a robust representation of the
true risk.
The study has shown that patients with Type 2 diabetes have
almost double the mortality rate compared with those without
diabetes, that younger patients with Type 2 diabetes have
three times the mortality rate of their peers without diabetes
and that the relative risk reduces with age. Our analysis on the
effects of BMI and smoking on the mortality of people with
diabetes provides strong evidence to advise patients with Type 2
diabetes of the benefits of smoking cessation and weight loss.
We believe these risk estimates will be of use in clinical decision
making, in particular when treating younger patients with
Type 2 diabetes, or when considering risk factor management
in the very elderly.
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